secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001193125-24-274856
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio reports mixed Phase 2a results: AA signal, AD miss
----------------------------------------------------------

- SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.
- SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).
- Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.
- Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.
- Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/0001193125-24-274856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/d903481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-274856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer